FI61689C - Foerfarande foer framstaellning av psykotropiska hydroxiacetoximderivat - Google Patents
Foerfarande foer framstaellning av psykotropiska hydroxiacetoximderivat Download PDFInfo
- Publication number
- FI61689C FI61689C FI751603A FI751603A FI61689C FI 61689 C FI61689 C FI 61689C FI 751603 A FI751603 A FI 751603A FI 751603 A FI751603 A FI 751603A FI 61689 C FI61689 C FI 61689C
- Authority
- FI
- Finland
- Prior art keywords
- compounds
- animals
- dose
- compound
- effect
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 6
- YDQKBKXXMMIUJV-UHFFFAOYSA-N 3-ethyl-2-hydroxyiminohexan-3-ol Chemical compound CCCC(O)(CC)C(C)=NO YDQKBKXXMMIUJV-UHFFFAOYSA-N 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 230000000506 psychotropic effect Effects 0.000 claims description 5
- 150000003793 acetoxime derivatives Chemical class 0.000 claims description 4
- KJOVOWDUYRMJEG-UHFFFAOYSA-N 2-hydroxyiminopropan-1-ol Chemical class OCC(C)=NO KJOVOWDUYRMJEG-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- AUDNFHXZPGAVRI-UHFFFAOYSA-N 3-ethyl-3-hydroxyhexan-2-one Chemical compound CCCC(O)(CC)C(C)=O AUDNFHXZPGAVRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 51
- 238000002474 experimental method Methods 0.000 description 29
- 230000001624 sedative effect Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 17
- 239000000935 antidepressant agent Substances 0.000 description 16
- 229940005513 antidepressants Drugs 0.000 description 16
- 230000001430 anti-depressive effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000932 sedative agent Substances 0.000 description 14
- 230000000202 analgesic effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000001773 anti-convulsant effect Effects 0.000 description 8
- 230000000147 hypnotic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 6
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 229960005152 pentetrazol Drugs 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- 229940125723 sedative agent Drugs 0.000 description 5
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 206010007776 catatonia Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229960002695 phenobarbital Drugs 0.000 description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960003147 reserpine Drugs 0.000 description 4
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
- 229960005453 strychnine Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 3
- HXFOAVBFYXPPEY-UHFFFAOYSA-N 5-(n-hydroxy-c-methylcarbonimidoyl)nonan-5-ol Chemical compound CCCCC(O)(C(C)=NO)CCCC HXFOAVBFYXPPEY-UHFFFAOYSA-N 0.000 description 3
- 206010014357 Electric shock Diseases 0.000 description 3
- 206010049816 Muscle tightness Diseases 0.000 description 3
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241001279009 Strychnos toxifera Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229960003861 mephenesin Drugs 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 230000002887 neurotoxic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000009864 tensile test Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 150000000475 acetylene derivatives Chemical class 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GOOCRIHPADOQAS-ZNUXJMJHSA-N (4ar,5as,8ar,13as,15as,15br)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2h-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one;sulfuric acid Chemical compound OS(O)(=O)=O.O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1.O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 GOOCRIHPADOQAS-ZNUXJMJHSA-N 0.000 description 1
- RWRUCOMSHXVBJK-UHFFFAOYSA-N 2-hydroxyimino-3-methylhexan-3-ol Chemical compound CCCC(C)(O)C(C)=NO RWRUCOMSHXVBJK-UHFFFAOYSA-N 0.000 description 1
- GXHGJNAXRSRWMS-UHFFFAOYSA-N 2-hydroxyiminohexan-3-ol Chemical compound CCCC(O)C(C)=NO GXHGJNAXRSRWMS-UHFFFAOYSA-N 0.000 description 1
- 241001182632 Akko Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000891 anti-reserpine Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- -1 ethanol Chemical compound 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960000412 strychnine sulfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
- C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7422033A FR2276033A1 (fr) | 1974-06-25 | 1974-06-25 | Derives actifs d'acetoxime, compositions therapeutiques les contenant ainsi que les procedes de preparation de ces derives et compositions |
FR7422033 | 1974-06-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI751603A FI751603A (xx) | 1975-12-26 |
FI61689B FI61689B (fi) | 1982-05-31 |
FI61689C true FI61689C (fi) | 1982-09-10 |
Family
ID=9140483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI751603A FI61689C (fi) | 1974-06-25 | 1975-05-30 | Foerfarande foer framstaellning av psykotropiska hydroxiacetoximderivat |
Country Status (21)
Country | Link |
---|---|
US (1) | US4032660A (xx) |
JP (1) | JPS5756912B2 (xx) |
AR (1) | AR207467A1 (xx) |
AT (1) | AT341489B (xx) |
BE (1) | BE830576A (xx) |
CA (1) | CA1032871A (xx) |
CH (1) | CH596155A5 (xx) |
DE (1) | DE2527907A1 (xx) |
DK (1) | DK144761C (xx) |
ES (1) | ES438861A1 (xx) |
FI (1) | FI61689C (xx) |
FR (1) | FR2276033A1 (xx) |
GB (1) | GB1453921A (xx) |
IE (1) | IE41623B1 (xx) |
IT (1) | IT1044296B (xx) |
NL (1) | NL7505205A (xx) |
NO (1) | NO140298C (xx) |
OA (1) | OA05037A (xx) |
SE (1) | SE422054B (xx) |
YU (1) | YU36696B (xx) |
ZA (1) | ZA753348B (xx) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237069A (en) * | 1979-07-02 | 1980-12-02 | Allied Chemical Corporation | Production of alpha-hydroxy oximes |
US5362408A (en) * | 1992-07-14 | 1994-11-08 | The Western Company Of North America | High temperature gel stabilizer for fracturing fluids |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3224873A (en) * | 1963-02-25 | 1965-12-21 | Gen Mills Inc | Liquid-liquid recovery of copper values using alpha-hydroxy oximes |
US3346523A (en) * | 1964-08-03 | 1967-10-10 | Exxon Research Engineering Co | Coating compositions made from oximes |
US3437454A (en) * | 1966-04-26 | 1969-04-08 | Kerr Mc Gee Chem Corp | Vanadium recovery from wet process phosphoric acid using alpha-hydroxy oximes |
US3794719A (en) * | 1972-02-25 | 1974-02-26 | Sec Corp | Reduction of nickel contamination by zinc in {60 -hydroxy oxime extract |
-
1974
- 1974-06-25 FR FR7422033A patent/FR2276033A1/fr active Granted
-
1975
- 1975-01-01 AR AR259338A patent/AR207467A1/es active
- 1975-05-02 NL NL7505205A patent/NL7505205A/xx not_active Application Discontinuation
- 1975-05-14 YU YU1225/75A patent/YU36696B/xx unknown
- 1975-05-23 ZA ZA00753348A patent/ZA753348B/xx unknown
- 1975-05-23 GB GB2274475A patent/GB1453921A/en not_active Expired
- 1975-05-23 IE IE1147/75A patent/IE41623B1/en unknown
- 1975-05-30 FI FI751603A patent/FI61689C/fi not_active IP Right Cessation
- 1975-06-05 US US05/584,176 patent/US4032660A/en not_active Expired - Lifetime
- 1975-06-17 IT IT24415/75A patent/IT1044296B/it active
- 1975-06-20 CH CH809975A patent/CH596155A5/xx not_active IP Right Cessation
- 1975-06-23 DE DE19752527907 patent/DE2527907A1/de not_active Ceased
- 1975-06-23 CA CA229,905A patent/CA1032871A/en not_active Expired
- 1975-06-24 NO NO752241A patent/NO140298C/no unknown
- 1975-06-24 DK DK285175A patent/DK144761C/da not_active IP Right Cessation
- 1975-06-24 SE SE7507253A patent/SE422054B/xx unknown
- 1975-06-24 BE BE157625A patent/BE830576A/xx not_active IP Right Cessation
- 1975-06-25 ES ES438861A patent/ES438861A1/es not_active Expired
- 1975-06-25 OA OA55536A patent/OA05037A/xx unknown
- 1975-06-25 AT AT487475A patent/AT341489B/de not_active IP Right Cessation
- 1975-06-25 JP JP50079704A patent/JPS5756912B2/ja not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ATA487475A (de) | 1977-06-15 |
AT341489B (de) | 1978-02-10 |
DK285175A (da) | 1975-12-26 |
AR207467A1 (es) | 1976-10-08 |
ES438861A1 (es) | 1977-05-16 |
JPS5756912B2 (xx) | 1982-12-02 |
DK144761B (da) | 1982-06-01 |
IT1044296B (it) | 1980-03-20 |
YU122575A (en) | 1982-06-18 |
US4032660A (en) | 1977-06-28 |
FI61689B (fi) | 1982-05-31 |
NO140298C (no) | 1979-08-08 |
FR2276033B1 (xx) | 1978-07-21 |
CH596155A5 (xx) | 1978-02-28 |
YU36696B (en) | 1984-08-31 |
ZA753348B (en) | 1976-05-26 |
NO140298B (no) | 1979-04-30 |
DE2527907A1 (de) | 1976-01-08 |
SE422054B (sv) | 1982-02-15 |
AU8163875A (en) | 1976-12-02 |
NL7505205A (nl) | 1975-12-30 |
IE41623B1 (en) | 1980-02-13 |
FI751603A (xx) | 1975-12-26 |
SE7507253L (sv) | 1975-12-29 |
OA05037A (fr) | 1980-12-31 |
GB1453921A (en) | 1976-10-27 |
IE41623L (en) | 1975-12-25 |
NO752241L (xx) | 1975-12-30 |
FR2276033A1 (fr) | 1976-01-23 |
CA1032871A (en) | 1978-06-13 |
BE830576A (fr) | 1975-12-24 |
JPS5123213A (xx) | 1976-02-24 |
DK144761C (da) | 1982-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maremmani et al. | QTc interval prolongation in patients on long-term methadone maintenance therapy | |
US4626549A (en) | Treatment of obesity with aryloxyphenylpropylamines | |
JPH01250315A (ja) | 脳機能改善剤 | |
FI72969B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbar 3-(2-morfolinoetylamino)-5-fenylpyridazin och av dess salter. | |
JPS5939418B2 (ja) | アリ−ルオキシフエニルプロピルアミン類の製法 | |
KR101986272B1 (ko) | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 | |
DK164852B (da) | N-phenylmethylenalkanamider med analgetisk virkning samt farmaceutiske praeparater indeholdende samme | |
DE2163911C3 (de) | 2-Aminomethyl-phenole, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel | |
DE2607592A1 (de) | Acetylenderivate von aminosaeuren sowie verfahren zu deren herstellung | |
PL118755B1 (en) | Process for preparing novel derivatives of phenethanolamine | |
US3205136A (en) | Antidepressant phenyloxyalkylamines | |
FI61689C (fi) | Foerfarande foer framstaellning av psykotropiska hydroxiacetoximderivat | |
EP1317426A1 (de) | Beta-thio-aminosäuren | |
US20060189612A1 (en) | Pharmaceutically active morpholinol | |
BR112019018966A2 (pt) | analógicos da deutetrabenazina, sua preparação e uso | |
DE1695604C3 (de) | 3-Methyl-3-(3-methylaminopropyl)-1-phenylindolin, dessen pharmazeutisch brauchbare Säureanlagerungssalze sowie diese enthaltende Antidepressiva | |
GB2168975A (en) | Amides and compositions thereof having anti-inflammatory and analgesic activity | |
DE2719607C2 (xx) | ||
DE2111775A1 (de) | 3-Aminocarbonyloxazolidin-2-onderivate,Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittelwirkstoff | |
US4898887A (en) | Compounds and compositions having anti-inflammatory and analgesic activity | |
FI61182B (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva butylaminderivat | |
DK174358B1 (da) | Terapeutiske midler indeholdende benzhydrylthiomethanderivater | |
KR940009791B1 (ko) | 퀴누클리딘 유도체의 제조방법 | |
CA1087987A (en) | Pharmaceutical composition containing 3- phenoxypyridine | |
Rao et al. | Kodasuri Veeravaippu’a sidha preparation, against Carrageenan induced paw edema and Cotton pellet induced granuloma in albino rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Patent lapsed |
Owner name: SANOFI |